Maintenance: Wednesday, 22 November 2017, 07:00-08:00
Maintenance work on the ZORA servers is provided. There may be short interruptions in the service between 07:00 and 08:00. Thank you for your patience.
Dummer, R; Duvic, M; Scarisbrick, J; Olsen, E A; Rozati, S; Eggmann, N; Goldinger, S M; Hutchinson, K; Geskin, L; Illidge, T M; Giuliano, E; Elder, J; Kim, Y H (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of Oncology, 25(9):1807-1812.
Olsen, E A; Whittaker, S J; Kim, Y H; Duvic, M; Prince, H M; Lessin, S R; Wood, G S; Willemze, R; Demierre, M F; Pimpinelli, N; Bernengo, M G; Ortiz-Romero, P L; Bagot, M; Estrach, T; Guitart, J; Knobler, R; Sanches, J A; Iwatsuki, K; Sugaya, M; Dummer, R; Pittelkow, M; Hoppe, R; Parker, S; Geskin, L; Pinter-Brown, L; Girardi, M; Burg, G; Ranki, A; Vermeer, M H; Horwitz, S; Heald, P; Rosen, S; Cerroni, L; Dreno, B; Vonderheid, E C (2011). Clinical end points and response criteria in mycosis fungoides and sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organisation for research and treatment of cancer. Journal of Clinical Oncology, 29(18):2598-2607.